CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
ARGOS-SC suprachoroidal pressure sensordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04773106
NCT04773106N/ACompleted

Follow-up of the First in Man, Prospective, Open-label, Single Arm, Multicenter Clinical Investigation to Assess the Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery (Follow-up Month 12 - Month 36)

Implandata Ophthalmic Products GmbH·interventional·Posted Feb 26, 2021·Updated May 18, 2025

In Brief

A clinical study evaluating ARGOS-SC suprachoroidal pressure sensor for Glaucoma and Open Angle Glaucoma. Completed, enrolled 22 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC system.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Switzerland

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 26, 2021
Enrollment StartFeb 20, 2020
Primary CompletionMar 2, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.4 years ago

Interventions

ARGOS-SC suprachoroidal pressure sensordevice

The ARGOS-SC pressure sensor was additionally implanted during routine local intraocular pressure lowering procedures in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.